RUNX1-RUNX1T1 represses CBFA2T3 gene transcription. (A) Expression levels of CBFA2T3 (left) and CD34 (right) and relative enrichment (log2 transformed) of patients with AML expressing high CBFA2T3 (left) and high CD34 (right) within each of the indicated AML subtypes. High and low expression are relative to the median expression level in all patient samples (n = 526). (B) Expression levels of NM_005187, NM_175931, and total CBFA2T3 in t(8;21) and non-t(8;21) AML patients in AML datasets indicated at the top. Raw data were downloaded from NIH dbGaP (TARGET, TCGA) and SRA (LEUCEGENE) repositories. The Gene Expression Omnibus repository accession numbers for LEUCEGENE are GSE49642, GSE52656, GSE62190, GSE66917, and GSE67039. (C) RT-qPCR results showing effects of RUNX1-RUNX1T1 knockdown in Kasumi-1 and SKNO-1 cells and overexpression of RUNX1-RUNX1T1 in U937 cells, HSPCs, and HEL cells on CBFA2T3 expression. (D) Effect of RUNX1-RUNX1T1 knockdown on NM_005187 and NM_175931 levels in Kasumi-1 cells assayed by using RNA-Seq. *P < .05; **P < .01; ***P < .001.